Our startup specializes in the cutting-edge field of extracellular vesicle (EV) biomarker discovery, utilizing single EV analysis and machine learning to revolutionize precision medicine. We provide a novel platform that significantly enhances the sensitivity and specificity of biomarker identification and allows healthcare professionals to diagnose conditions at an early stage, facilitating timely and personalized treatment options. We are committed to improving patient outcomes by bridging critical gaps in current diagnostic biomarkers. Our approach holds the potential to transform therapeutic strategies across a spectrum of diseases. With a focus on innovation and a strong IP strategy, we aim to lead the market in delivering robust and data-driven solutions for biomarker discovery.
Life sciences and cleantech startups compete for CHF 100,000 (startupticker.ch)
DayOne Accelerator reveals latest cohort (startupticker.ch)
CHF 150,000 from Venture Kick to bring precision diagnostics to cancer immunotherapies (startupticker.ch)
Venture Leaders Biotech scale new heights in Boston (venturelab.swiss)
EVIIVE: The Venture Leader Biotech developing the next-generation liquid biopsy solution (venturelab.swiss)
The road to Boston: Venture Leaders Biotech 2024 kick-off their roadshow at Swiss Biotech Day (venturelab.swiss)
Venture Leaders Biotech 2024: 10 innovative startups selected for the Boston roadshow (venturelab.swiss)
The Biomedical Entrepreneurship ecosystem: Turning cutting-edge research into viable ventures (venturelab.swiss)
Eviive appoints Sandeep Wontakal MD. PhD as clinical & medical advisor
Eviive received Innosuisse initial coaching award
Eviive starts collaborating with Synthex. Inc
Eviive starts collaborating with University Hospital Zurich ICU
Eviive starts collaborating with NCKU Hospital in Taiwan